Researchers identify novel molecular mechanism involved in Alzheimer’s
WINSTON-SALEM, N.C. – Feb. 11, 2019 – Researchers at Wake Forest Baptist Health have identified a novel mechanism and potential new therapeutic target for Alzheimer’s disease (AD).
The findings are published in the current issue of the Journal of Clinical Investigation.
“Alzheimer’s is such a devastating disease and currently there is no cure or effective therapy,” said Tao Ma, Ph.D., assistant professor of gerontology and geriatric medicine at Wake Forest School of Medicine, part of Wake Forest Baptist Health.
“All completed clinical trials of new drugs have failed so there is clearly a need for novel therapeutic targets for potential treatments.”
Alzheimer’s is characterized by profound memory loss and synaptic failure. Although the exact cause of Alzheimer’s remains unclear, it is well established that maintaining memory and synaptic plasticity requires protein synthesis.
Ma’s team and others recently have shown AD-associated activation of a signaling molecule termed eEF2K leads to inhibition of protein synthesis. In this study they wanted to determine if suppression of eEF2K could improve protein synthesis capacity and consequently alleviate the cognitive and synaptic impairments associated with the disease.
The researchers used a genetic approach to repress the activity of eEF2K in two different Alzheimer’s mouse models. They found that genetic suppression of eEF2K prevented memory loss in those animal models and significantly improved synaptic function.
“These findings are encouraging and provide a new pathway for further research,” Ma said.
His team hopes next to test this approach in additional animal studies and eventually in human trials using small molecule inhibitors targeting eEF2K.
This work was supported by NIH grants K99/R00 AG044469, R01 AG055581, R01 AG056622, F31AG055264, F31AG054113, P50AG005136, U01AG006781; Alzheimer’s Association grant NIRG-15-362799; BrightFocus Foundation grant A2017457S; Wake Forest Alzheimer’s Disease Core Center pilot grant P30AG049638; Wake Forest Clinical and Translational Science Institute pilot grant, and the Nancy and Buster Alvord Endowment.